These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 20422780)

  • 21. New agents modulating the renin-angiotensin-aldosterone system-Will there be a new therapeutic option?
    Gromotowicz-Poplawska A; Szoka P; Kolodziejczyk P; Kramkowski K; Wojewodzka-Zelezniakowicz M; Chabielska E
    Exp Biol Med (Maywood); 2016 Nov; 241(17):1888-1899. PubMed ID: 27439538
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Participation of the mineralocorticoid receptor in cardiac and vascular remodeling.
    Fiebeler A; Haller H
    Nephron Physiol; 2003; 94(3):p47-50. PubMed ID: 12902615
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of brain corticosterone and aldosterone in central angiotensin II-induced hypertension.
    Huang BS; White RA; Ahmad M; Leenen FH
    Hypertension; 2013 Sep; 62(3):564-71. PubMed ID: 23856493
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aldosterone Synthase Inhibitors and Mineralocorticoid Receptor Antagonists: Competitors or Collaborators?
    Pitt B; Williams GH
    Circulation; 2024 Feb; 149(6):414-416. PubMed ID: 38315762
    [No Abstract]   [Full Text] [Related]  

  • 25. Central mineralocorticoid receptors and the role of angiotensin II and glutamate in the paraventricular nucleus of rats with angiotensin II-induced hypertension.
    Gabor A; Leenen FH
    Hypertension; 2013 May; 61(5):1083-90. PubMed ID: 23509081
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology.
    Wilkinson-Berka JL; Tan G; Jaworski K; Harbig J; Miller AG
    Circ Res; 2009 Jan; 104(1):124-33. PubMed ID: 19038868
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of Aldosterone in Renal Fibrosis.
    Shrestha A; Che RC; Zhang AH
    Adv Exp Med Biol; 2019; 1165():325-346. PubMed ID: 31399972
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vascular actions of aldosterone.
    Briet M; Schiffrin EL
    J Vasc Res; 2013; 50(2):89-99. PubMed ID: 23172373
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adipocyte-derived factors regulate vascular smooth muscle cells through mineralocorticoid and glucocorticoid receptors.
    Nguyen Dinh Cat A; Briones AM; Callera GE; Yogi A; He Y; Montezano AC; Touyz RM
    Hypertension; 2011 Sep; 58(3):479-88. PubMed ID: 21788604
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Macrophage mineralocorticoid receptor signaling plays a key role in aldosterone-independent cardiac fibrosis.
    Bienvenu LA; Morgan J; Rickard AJ; Tesch GH; Cranston GA; Fletcher EK; Delbridge LM; Young MJ
    Endocrinology; 2012 Jul; 153(7):3416-25. PubMed ID: 22653557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Cardioprotective effect of aldosterone antagonists for ventricular remodeling].
    Tatsumi T; Matsubara H
    Nihon Rinsho; 2006 Jul; 64 Suppl 5():524-9. PubMed ID: 16897886
    [No Abstract]   [Full Text] [Related]  

  • 32. Adipocyte Mineralocorticoid Receptor.
    Infante M; Armani A; Marzolla V; Fabbri A; Caprio M
    Vitam Horm; 2019; 109():189-209. PubMed ID: 30678856
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aldosterone, mineralocorticoid receptor and the metabolic syndrome: role of the mineralocorticoid receptor antagonists.
    Ronconi V; Turchi F; Appolloni G; di Tizio V; Boscaro M; Giacchetti G
    Curr Vasc Pharmacol; 2012 Mar; 10(2):238-46. PubMed ID: 22022770
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is the mineralocorticoid receptor a potential target for stroke prevention?
    Osmond JM; Rigsby CS; Dorrance AM
    Clin Sci (Lond); 2008 Jan; 114(1):37-47. PubMed ID: 18047468
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insulin resistance in chronic kidney disease is ameliorated by spironolactone in rats and humans.
    Hosoya K; Minakuchi H; Wakino S; Fujimura K; Hasegawa K; Komatsu M; Yoshifuji A; Futatsugi K; Shinozuka K; Washida N; Kanda T; Tokuyama H; Hayashi K; Itoh H
    Kidney Int; 2015 Apr; 87(4):749-60. PubMed ID: 25337775
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Renin-aldosterone and bone metabolism].
    Ikeda K
    Clin Calcium; 2014 Jun; 24(6):885-91. PubMed ID: 24870840
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: Beneficial effects of mineralocorticoid receptor blocker.
    Ohtani T; Ohta M; Yamamoto K; Mano T; Sakata Y; Nishio M; Takeda Y; Yoshida J; Miwa T; Okamoto M; Masuyama T; Nonaka Y; Hori M
    Am J Physiol Regul Integr Comp Physiol; 2007 Feb; 292(2):R946-54. PubMed ID: 17023667
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathophysiological roles of aldosterone and mineralocorticoid receptor in the kidney.
    Rafiq K; Hitomi H; Nakano D; Nishiyama A
    J Pharmacol Sci; 2011; 115(1):1-7. PubMed ID: 21186336
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of intracardiac renin-angiotensin-aldosterone system in extracellular matrix remodeling.
    Lijnen PJ; Petrov VV
    Methods Find Exp Clin Pharmacol; 2003 Sep; 25(7):541-64. PubMed ID: 14571285
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aldosterone Effect on Cardiac Structure and Function.
    Al-Hashedi EM; Abdu FA
    Curr Cardiol Rev; 2024; 20(4):e290224227534. PubMed ID: 38425104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.